Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: A meta-analysis of randomized trials

Article Abstract:

Data for all randomized trials conducted with abciximab in ST-segment elevation myocardial infarction (STEMI) are combined. The results revealed that, when compared with the control group, adjunctive abciximab for STEMI is associated with a significant reduction in 30-day and long-term mortality in patients treated with primary angioplasty but not in those receiving fibrinolysis.

United States, Science & research, Care and treatment, Research, Dosage and administration, Abciximab

---

Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors

Article Abstract:

Giving patients with coronary artery disease a stent plus the drug abciximab appears to be the most effective treatment for preventing a heart attack. A stent is a small cylindrical device that is inserted into an artery to keep it open. Abciximab is a drug that prevents the formation of blood clots. Researchers randomly assigned 2,399 patients with coronary artery disease to receive a stent only, a stent and abciximab, or balloon angioplasty plus abciximab. The lowest rate of heart attack and death occurred in the group that received a stent and abciximab.

Statistical Data Included, Evaluation, Product/Service Evaluation, Prevention, Stent (Surgery), Stents, ReoPro (Medication)

---

Similar abstracts:

• Abstracts: Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization
• Abstracts: Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/ IIIa blockade during percutaneous coronary revascularization
• Abstracts: Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism
• Abstracts: Levels of vaginal secretory leukocyte protease inhibitor are decreased in women with lower reproductive tract infections
• Abstracts: Effects of Atorvastatin of Early Recurrent Ischemic Events in Acute Coronary Syndromes: A Randomized Controlled Trial

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.